Short answer
MAXCYTE, INC. (MXCT) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $6M (up 34.6% year over year) with net income of −$5M.
Q3 2026 key financials · XBRL
- Revenue
- $6M
- +34.6% YoY · +25.5% QoQ
- Net income
- −$5M
- +61.6% YoY · +46.3% QoQ
- Operating margin
- -97.5%
- Gross margin
- 136.7%
- EPS (diluted)
- −$0.04
- +66.7% YoY · +55.6% QoQ
Source: XBRL data from the MAXCYTE, INC. (MXCT) Q3 2026 10-Q on SEC EDGAR. USD.
MAXCYTE, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $10.2M, up 49% YoY from $6.8M, driven by SPL milestones and royalties
- Gross margin 83% vs 77% YoY, supported by higher-margin milestone and royalty revenue
- Best line: instrument revenue $2.8M, up 102%; weakest: Assay Service revenue down 83%
- Operating cash outflow $18.3M for nine months, versus $31.7M YoY; $5.5M stock repurchases
- Outlook: near-term operating losses, revenue volatility, and proposed Akron acquisition requiring $105.0M cash plus $22.0M initial debt draw
Risk Factors
- Newly added risk: proposed Akron acquisition may fail or be delayed, triggering unrecoverable transaction costs and potential stock-price decline
- Acquisition consideration: $105.0 million cash, 20,639,733 shares, and $20.0 million guaranteed deferred payments due January 2028 and January 2029
- Regulatory and compliance risk: Akron integration requires cGMP compliance and public-company financial controls
- Operational risk: limited experience with Akron’s reagent business may hinder integration, customer retention, and cross-selling
- Financial risk: proposed debt includes $20.0 million term borrowing and $2.0 million revolver borrowing at closing, with variable SOFR-based interest
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MAXCYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.